HELLO CHINA

INDUSTRY CLUSTER · Consumer goods

Shanghai Fengxian cosmetics

Fengxian cosmetics use Oriental Beauty Valley to connect brands and services across formulation, ingredients, packaging, scaled production, quality compliance and consumer channels.

Formation and regional foundations

Local production, Shanghai brand and research resources, Oriental Beauty Valley services and a growing contract-manufacturing base shaped the industry. Fengxian cosmetics output above designated size reached CNY 14.4 billion in 2024.

Turning a laboratory cosmetic into a production item requires ingredients and packaging approval, scale-up, filling, testing, labelling and post-market feedback. The same formula can change stability or user experience after a new pump, fragrance lot or production line. Fengxian concentrates brands, R&D and contract manufacturers, so project boundaries run from formula rights through complaint handling.

Core geography: Oriental Beauty Valley R&D services, Fengxian production and Shanghai consumer channels

Fengxian Cosmetics Development and Delivery Route

Product Definition, Formula, Inputs, Scale-Up, Filling, Tests and Market Feedback

The route does not imply shared formulas, lines, brands or product responsibility among Chando, COSMAX and Interfila.

  • Consumer, category and benefit target — Defines use area, consumer, format, sensory target, directions, price and claim boundary.
  • Formula development and sample evaluation — Manages formula revisions, ingredient function, compatibility, stability, microbiology, sensory work and evidence.
  • Ingredients, packaging and supply changes — Checks specification, supplier, lot, tests, pumps, seals, labels and substitution approval.
  • Scale-Up, production and cleaning changeover — Controls charging, temperature, mixing, homogenisation, vacuum, hold time, cleaning and cross-contamination.
  • Filling, coding and release — Verifies fill, seal, appearance, microbiology, chemistry, lot code, retention and shipping pack.
  • Channels, complaints and improvement — Links sales lots, consumer feedback, adverse reactions, returns, causes and corrections.

01 · Output, Growth, R&D Centres and Patents Use Different Denominators

Economic output and innovation counts cannot combine into one company capability.

Shanghai industry-planning information gives RMB 14.4 billion of 2024 Fengxian cosmetics output above designated size, up 13.8 percent year on year; forty-nine local cosmetics firms have R&D centres and cumulative patents exceed 1,000. A separate 2024 ministry list confirms the related specialised cluster. The measures cover output, change, company facilities and cumulative knowledge assets.

Above-scale output excludes some small firms and is neither sales nor profit. Forty-nine R&D-centre firms may each hold several patents, while more than 1,000 is cumulative and does not yield current-year average innovation. Cluster recognition likewise does not prove a formula or plant compliant.

A regional dashboard labels output and growth with 2024 and the above-scale boundary and gives the company count and cumulative basis for R&D centres and patents. Company assessment separately checks entity, production permission, product range, current R&D staff and translatable work. Company revenue or patent count uses its own disclosure only.

  • The 2024 date, above-scale scope and cumulative basis remain visible.

02 · A Chando Product Brief Must Define Benefit and Sensory Experience Together

A market concept needs a measurable formula and consumer setting.

Fengxian industry information shows regional R&D-centre and patent accumulation, while the Chando site offers brand, R&D and corporate routes. The regional count of forty-nine R&D-centre firms is not a Chando institution count, and cumulative patents do not belong to it. A specific new product still depends on Chando project files.

Ideas such as fresh, repairing or brightening affect format, phase balance, skin feel, fragrance and evidence. Pursuing immediate lightness can reduce stability margin in some environments, while more active ingredient may change colour and packaging compatibility. Approving marketing language alone does not create an executable formula target.

A Chando brief states use area, consumer, frequency, format, skin feel, fragrance, benefit claim, price and package. R&D turns these into formula specifications, evaluation methods and sample revisions. Claim evidence, stability and consumer work all correspond to the final formula and pack.

  • Claims, formula, tests and packaging use one product revision.

03 · COSMAX Contract Production Starts with Formula Transfer and Equipment Fit

A laboratory beaker result does not scale proportionally to a production vessel.

Fengxian industry information describes scaled production and R&D, while COSMAX China information confirms a Fengxian manufacturing address and cosmetics capability. Regional output and growth are not COSMAX revenue or orders. Company capability still needs a match to format, batch size, equipment and schedule.

After scale-up, mixing flow, heat transfer, charging time and vacuum efficiency change in emulsification, dispersion or dissolution. A smooth laboratory cream can develop particles, bubbles or viscosity differences in a large vessel. Ingredient order and intermediate hold also affect final condition.

A formula transfer to COSMAX uses a controlled file for ingredient codes, charging order, temperature range, mixing and homogenisation stages, vacuum, in-process samples and end decision. A trial lot records actual parameters and compares with the laboratory sample. Commercial processing is fixed only after consecutive lots meet specifications.

  • Charging order, temperature, shear and hold time form controlled parameters.

04 · Manufacturing Supervision Must Resolve Registrant and Factory Duties

Contract manufacturing does not transfer every product duty from the brand owner.

The ministry list confirms the Fengxian cosmetics specialised cluster, while national medical-products provisions set supervision for cosmetics production and marketing. Cluster status describes concentration and the provisions address company and product duties. Neither completes permission, filing or product release for a specific entity.

Brand owner, registrant or notifier, contract manufacturer and distributor may be different entities. If the factory starts a formula change, the brand approves labels and a channel receives complaints, disconnected information delays action. A contract saying only “follow regulations” still does not say who performs each task.

The quality agreement assigns formula and ingredient approval, supplier change, manufacturing deviation, test release, label approval, retention, complaints, adverse reactions and recall with notification times. The parties regularly reconcile lots and market feedback. A major change receives technical and compliance decisions before implementation.

  • Formula, release, change, complaint and recall are assigned item by item.

05 · A Chando-COSMAX Relationship Requires Its Own Evidence

A shared Fengxian location does not mean shared formulas, lines or products.

The Chando site provides brand and R&D routes, while COSMAX information presents Fengxian manufacturing capability. Both operate in the Fengxian cosmetics industry, but the public information alone confirms no manufacturing relationship for a product. Regional output, R&D-centre count and patents also do not prove cooperation.

A brand can make internally or use one or several factories, and one manufacturer can serve many customers. Formula, fragrance, packaging and sales information have project-specific access. Assuming data access because both are local creates intellectual-property and confidentiality risk.

Only an actual contract creates authorised staff, document exchange, formula revision, material codes, lot mapping and sample ownership for a project. System accounts receive least privilege and close at project end. An unauthorised company name does not appear in production or marketing material.

  • Brand information and batch records connect only within an authorised project.

06 · The Interfila Production Node Must Match Category, Pack and Market

Global-network information does not replace confirmation at the Fengxian plant.

Fengxian industry planning provides regional manufacturing and innovation context, while the Intercos global-production network identifies the Interfila China entity and Fengxian production node. A global network describes group geography, but an order still resolves to the China entity and actual plant. Fengxian output and patents are not Interfila company data.

Colour cosmetics, skin care, cleansing and other categories need different equipment, cleaning changeover, shade control and pack assembly. Across markets, labels, restricted ingredients and responsible entity can change. Experience at another group plant does not directly represent a Fengxian line.

An Interfila enquiry confirms contracting entity, production address, category, lot size, line, critical equipment, cleaning level, package fit and destination. The factory returns formal deviations and schedule. First-lot batch records, test reports and labels show consistent entity and revision.

  • Entity, address, line, product and destination are checked item by item.

07 · Microbial, Wrong-Input and Exaggerated-Claim Risks Need Separate Responses

Manufacturing exceptions and market wording cannot share one quality status.

Fengxian cluster status describes an industry base, while cosmetics supervision provisions supply the regulatory framework. A mature industry can still face microbial contamination, wrong inputs, package compatibility, label errors and claims beyond evidence. Regional growth and patent count do not reduce lot-level product risk.

A microbial exception may begin in ingredients, water, equipment, environment or packaging; a wrong input follows supply and weighing records; a claim issue concerns evidence and market material. All can stop shipment but need different samples, teams and corrections. A generic quality problem hides the affected scope.

A microbial event isolates affected lots and reviews environment and process, a wrong input holds the relevant materials and product flow, and an unsupported claim stops the corresponding page and collateral. Named owners decide product safety, market notice and regulatory contact. After closure, the related controls, responsibilities and staff training are updated together.

  • Each issue expands by lot, affected consumer and responsible step.

08 · Use One Emulsion to Close a Fengxian Product-Launch Cycle

Consumer target, formula, factory, pack and channel align in the first lot.

Fengxian industry information provides an R&D and manufacturing setting, the Chando site offers a brand R&D route, and Interfila information gives another Fengxian production node. The firms can be studied separately as brand and manufacturer. Public material does not show joint development or production of an emulsion.

The pilot first fixes target consumer, skin feel, benefit boundary, price and pump bottle and then creates formula and packaging samples. Stability, compatibility, microbiology and consumer work use one revision. After the actual manufacturer is selected, formula transfer, trial production and batch-record review follow.

The first market lot links production code, ingredients, packaging, tests, retention, channel and complaints and reviews pump, odour, feel, irritation and transit issues weekly. Causes are separated among product, package and use. Size, fragrance or channel expands only after the stable observation period.

  • Formats expand only after first-lot stability and market feedback.

Sources and reading notes

The RMB 14.4 billion output and 13.8 percent year-on-year growth refer to Fengxian cosmetics firms above designated size in 2024. Forty-nine firms with R&D centres and more than 1,000 cumulative patents are regional industry measures and cannot be allocated to Chando, COSMAX or Interfila. Company sites identify their separate brand, R&D or production routes only.

  • In 2024, Fengxian cosmetics output above designated size was CNY 14.4 billion, up 13.8 percent year on year.
  • Forty-nine Fengxian cosmetics firms have R&D centres, with more than 1,000 cumulative patents.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Chando Group — Shanghai Municipal Government documents the local base of Shanghai Fengxian cosmetics. The company’s official site describes related products or services and an operating presence in Shanghai.
  • COSMAX China — Shanghai Municipal Government documents the local base of Shanghai Fengxian cosmetics. The company’s official site describes related products or services and an operating presence in Shanghai.
  • Interfila Shanghai — Shanghai Municipal Government documents the local base of Shanghai Fengxian cosmetics. The company’s official site describes related products or services and an operating presence in Shanghai.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.